Previous 10 | Next 10 |
Noteworthy events during the week of May 12 - 18 for healthcare investors. More news on: Johnson & Johnson, Insmed Incorporated, Innovate Biopharmaceuticals, Inc., Healthcare stocks news, , Read more ...
RALEIGH, N.C., May 09, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for immuno-inflammatory disease, announced that it plans to host an Analyst Event on M...
RALEIGH, N.C., May 01, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) today announced the closing of its previously announced registered direct offering of 4,318,272 shares of common stock at a purchase price of $2.025 per share, for aggregate gross proceeds of ...
Nano cap Innovate Biopharmaceuticals ( INNT -20% ) is down on a healthy 44x surge in volume in reaction to its direct offering of ~4.3M common shares at $2.025 pre share to institutional investors. Gross proceeds should be ~$8.7M. More news on: Innovate Biopharmaceuticals, Inc., Health...
RALEIGH, N.C., April 29, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) today announced that it has entered into securities purchase agreements with certain institutional investors providing for the purchase and sale of 4,318,272 shares of common stock at a purc...
Innovate Biopharmaceuticals, Inc. (INNT) Q1 2019 Results Earnings Conference Call April 29, 2019 08:00 AM ET Company Participants Jennifer Zimmons - Investor Relations Sandeep Laumas - Executive Chairman and Chief Executive Officer Patrick Griffin - Chief Medical Officer Pr...
Precipio (NASDAQ: PRPO ) +38% on first major international services contract. More news on: Precipio, Inc., Innovate Biopharmaceuticals, Inc., Changyou.com Limited, Stocks on the move, Read more ...
Nano cap Innovate Biopharmaceuticals (NASDAQ: INNT ) jumps 27% premarket on increased volume in response to its announcement of encouraging data on lead drug larazotide acetate in a mouse model of NASH. The results will be presented at the Analyst Meeting at the Digestive Dis...
Continued execution toward start of the first phase 3 celiac disease clinical trial in the current quarter with key sites for trial launch selected and active recruitment efforts underway NASH Data Presentation at Analyst Meeting at Digestive Disease Week (DDW) conference on May 20, 2...
RALEIGH, N.C., April 26, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced that company executives intend to ho...
News, Short Squeeze, Breakout and More Instantly...
Innovate Biopharmaceuticals Inc. Company Name:
INNT Stock Symbol:
NASDAQ Market:
Innovate Biopharmaceuticals Inc. Website:
Completes concurrent financing of ~$22 million led by Orbimed Advisors, LLC Lead program, a proprietary long-acting GLP-1 receptor agonist, starting Phase 2 trial for Short Bowel Syndrome (SBS), an underserved, orphan condition Continued Phase 3 trial of larazotide; first and on...
RALEIGH, NC / ACCESSWIRE / March 20, 2020 / Innovate Biopharmaceuticals, Inc. (the "Company" or "Innovate") (NASDAQ:INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced that it has filed its 2019 Annual Report on Form...
Israeli Regulatory Approvals Appear on Track for Late March 2020 to Allow Closing of the Merger RALEIGH, NC / ACCESSWIRE / March 11, 2020 / Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT), a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune a...